NO934776D0 - Rensing av rekombinant apoliproteiner E fra bakterier - Google Patents

Rensing av rekombinant apoliproteiner E fra bakterier

Info

Publication number
NO934776D0
NO934776D0 NO934776A NO934776A NO934776D0 NO 934776 D0 NO934776 D0 NO 934776D0 NO 934776 A NO934776 A NO 934776A NO 934776 A NO934776 A NO 934776A NO 934776 D0 NO934776 D0 NO 934776D0
Authority
NO
Norway
Prior art keywords
analog
apoe
recombinant
purification process
fatty acids
Prior art date
Application number
NO934776A
Other languages
English (en)
Other versions
NO934776L (no
Inventor
Ruth Lifshitz
Meir Fischer
Benjamin Greenman
Daniel Bartfeld
Original Assignee
Bio Technology General Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NZ238813A external-priority patent/NZ238813A/en
Application filed by Bio Technology General Corp filed Critical Bio Technology General Corp
Publication of NO934776D0 publication Critical patent/NO934776D0/no
Publication of NO934776L publication Critical patent/NO934776L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/803—Physical recovery methods, e.g. chromatography, grinding
NO934776A 1991-06-26 1993-12-22 Rensing av rekombinant apoliproteiner E fra bakterier NO934776L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US1991/004553 WO1993000443A1 (en) 1991-06-26 1991-06-26 Purification of recombinant apolipoprotein e from bacteria
NZ238813A NZ238813A (en) 1991-06-26 1991-07-01 Production and purification of apolipoprotein e (apo e) and its use
US08/333,872 US5525472A (en) 1991-06-26 1994-11-03 Method for production and purification or recombinant Apolipoprotein E from bacteria

Publications (2)

Publication Number Publication Date
NO934776D0 true NO934776D0 (no) 1993-12-22
NO934776L NO934776L (no) 1994-02-17

Family

ID=27353645

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934776A NO934776L (no) 1991-06-26 1993-12-22 Rensing av rekombinant apoliproteiner E fra bakterier

Country Status (3)

Country Link
US (1) US5525472A (no)
NO (1) NO934776L (no)
WO (1) WO1993000443A1 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2167942A1 (en) * 1993-08-12 1995-02-23 Tikva Vogel Method of inhibiting kaposi's sarcoma
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US6277874B1 (en) * 1996-07-09 2001-08-21 University Of Cincinnati And Apologic, Incorporated Methods for the treatment of apolipoprotein E related diseases
WO1998011140A1 (en) * 1996-09-11 1998-03-19 Pharmacia & Upjohn Ab A process for purifying apolipoproteins and a composition for use in the process
NZ334589A (en) * 1996-09-11 2000-07-28 Pharmacia & Upjohn Ab Aqueous two-phase system for purifying apolipoproteins
EP1267908B1 (en) * 2000-03-03 2004-05-06 GlaxoSmithKline Biologicals S.A. Vaccine for the treatment of atherosclerosis
US6555391B1 (en) * 2000-08-15 2003-04-29 Baxter International, Inc. Methods of conditioning an affinity resin after storage
CN1268641C (zh) * 2000-11-10 2006-08-09 普罗蒂奥制药公司 载脂蛋白类似物
CN1312273C (zh) * 2002-09-30 2007-04-25 中国科学院沈阳应用生态研究所 一种光合细菌培养基用添加剂
DE10309691B4 (de) * 2003-02-28 2018-10-04 Hans-Knöll-Institut für Naturstoff-Forschung e.V. Gewinnung von löslichen Proteinen aus der Biomasse rekombinanter Mikroorganismen
GB0329254D0 (en) * 2003-12-17 2004-01-21 Univ Manchester Treatment of viral infections
US8013122B2 (en) * 2006-12-20 2011-09-06 Kieu Hoang Method of purifying apolipoprotein A-1
CN100586958C (zh) * 2006-12-20 2010-02-03 上海莱士血液制品股份有限公司 高纯度载脂蛋白a-i的制备方法
US8324366B2 (en) * 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
KR20210158864A (ko) 2008-11-10 2021-12-31 알닐람 파마슈티칼스 인코포레이티드 치료제 운반용 신규 지질 및 조성물
AU2010208035B2 (en) 2009-01-29 2016-06-23 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
WO2010105209A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
EP3097908A1 (en) 2009-05-05 2016-11-30 Arbutus Biopharma Corporation Lipid compositions
PT3431076T (pt) 2009-06-10 2021-10-26 Arbutus Biopharma Corp Formulação lipídica melhorada
WO2011020023A2 (en) 2009-08-14 2011-02-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20120245076A1 (en) * 2009-09-03 2012-09-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering rnai using apoe
CA2783372C (en) 2009-12-07 2019-07-16 Muthiah Manoharan Compositions for nucleic acid delivery
ES2749426T3 (es) 2009-12-18 2020-03-20 Univ British Columbia Métodos y composiciones para administración de ácidos nucleicos
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
EP2569276B1 (en) 2010-05-12 2021-02-24 Arbutus Biopharma Corporation Novel cationic lipids and methods of use thereof
US10077232B2 (en) 2010-05-12 2018-09-18 Arbutus Biopharma Corporation Cyclic cationic lipids and methods of use
EP3254672A1 (en) 2010-06-03 2017-12-13 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
CN110123830A (zh) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
DK2663548T3 (en) 2011-01-11 2017-07-24 Alnylam Pharmaceuticals Inc PEGYLED LIPIDS AND THEIR USE FOR PHARMACEUTICAL SUPPLY
DK2767546T3 (en) 2011-02-07 2019-02-04 Cerenis Therapeutics Holding Sa Lipoprotein complexes and their preparation and uses
AU2012315965A1 (en) 2011-09-27 2014-04-03 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted PEGylated lipids
WO2014011908A1 (en) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
US4656132A (en) * 1984-03-28 1987-04-07 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
US4943527A (en) * 1985-10-04 1990-07-24 California Biotechnology Inc. Mature apoai protein production under serum free culturing conditions
US5049488A (en) * 1985-11-08 1991-09-17 Genentech, Inc. Method and nucleic acid for the preparation of lecithin:cholesterol acyltransferase
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
CA1335077C (en) * 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum

Also Published As

Publication number Publication date
WO1993000443A1 (en) 1993-01-07
US5525472A (en) 1996-06-11
NO934776L (no) 1994-02-17

Similar Documents

Publication Publication Date Title
NO934776D0 (no) Rensing av rekombinant apoliproteiner E fra bakterier
Sun et al. Lactic acid-producing probiotic Saccharomyces cerevisiae attenuates ulcerative colitis via suppressing macrophage pyroptosis and modulating gut microbiota
DE3152001C2 (no)
EP0134385B1 (en) A protein having cell growth stimulating action, composition thereof and method for producing the same
Bond et al. Characterization of markedly lipid‐dependent Malassezia pachydermatis isolates from healthy dogs
NL990016I2 (nl) Expressie van biologisch actieve analogen van uit bloedplaatjes afgeleide groeifactor in eukaryotische cellen.
IL137848A (en) Indole-3-propionic acids and salts and esters thereof for use as medicaments
ATE25245T1 (de) Chinoloncarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel.
ATE321141T1 (de) Verfahren zur herstellung eines rekombinanten polypeptids unter hinzufügung eines chymotrypsinhemmstoffes zum zellkulturmedium
Sharma et al. Swarming: a coordinated bacterial activity
MA20411A1 (fr) Procede de preparation de polypeptides ayant l'activite du gamma-interferon humain
Moullier et al. Long-term delivery of a lysosomal enzyme by genetically modified fibroblasts in dogs
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
Long et al. Therapeutic potential of exosomes from adipose-derived stem cells in chronic wound healing
Kabashima et al. Partial characterization of an interleukin-1-like factor in human gingival crevicular fluid from patients with chronic inflammatory periodontal disease
JP2022078948A (ja) 乳酸菌発酵産物含有外傷外用組成物
SE9704584D0 (sv) Formation of fatty acid
AU654651B2 (en) Method of preparing lysozyme dimers
KUROBANE et al. Biochemical improvement after treatment by bone marrow transplantation in I-cell disease
CN114470007A (zh) 含乳酸菌发酵产物之创伤外用组合物及其用途
MD3781F1 (en) Process for obtaining an antioxidant thermostable preparation from Spirulina platensis cyanobacterium biomass
DE2346335A1 (de) Auf mikrobiellem weg hergestellte lipase, sowie verfahren zu deren herstellung
Cooper et al. The prevalence of bacteria and implications for infection control
Spector et al. Proliferation of macrophages in inflammation
Foster et al. Improved methodologies for the isolation and purification of tropoelastin